Subtype
Large Intestinal Neoplasm
CI-CAN-00001062Explore in graph →
Non-malignant1,849 active trials21 approved drugs383 evidence items
- NCIt
- C215201
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001062Explore in graph →
Clinical trials
8,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06374173 | A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 123 | Hefei TG ImmunoPharma Co., Ltd.OTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT05518201 | Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT01972373 | Visualization of Rectal Cancer During Endoscopy, Using a Fluorescent Tracer(RAPIDO-TRACT) | completed | Phase 1 | 30 | University Medical Center GroningenOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04638036 | Fluorescence Molecular Endoscopy and Molecular Fluorescence-guided Surgery in Locally Advanced Rectal Cancer(TRACT-II) | completed | Phase 1 | 11 | University Medical Center GroningenOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06358053 | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | not yet recruiting | Phase 1 | 24 | Corregene Biotechnology Co., LtdINDUSTRY | 0 | Apr 10, 2024 | clinicaltrials |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | suspended | Phase 1 | 30 | DNAtrix, Inc.INDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT03317119 | Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery | completed | Phase 1 | 26 | City of Hope Medical CenterOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT06202001 | Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients | recruiting | Phase 1 / Phase 2 | 70 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT01761240 | Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Mar 29, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT03373188 | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | completed | Phase 1 | 10 | Emory UniversityOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06225622 | Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | unknown | Phase 1 | 78 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06304597 | Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy(PREDICT) | unknown | Phase 1 | 18 | University Medical Center GroningenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06300489 | Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer | unknown | Phase 1 | 30 | Zhejiang Cancer HospitalOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT05111860 | Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy | unknown | Phase 1 / Phase 2 | 20 | Shanghai Minimally Invasive Surgery CenterOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT00019006 | Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00020267 | Vaccine Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | terminated | Phase 1 / Phase 2 | 11 | NKGen Biotech, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06283303 | A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer | unknown | Phase 1 | 8 | China Medical University, ChinaOTHER | 0 | Feb 29, 2024 | clinicaltrials |
| NCT06075849 | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | unknown | Phase 1 | 30 | Panolos BioscienceINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06270017 | Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars(ZEBRA-COLON) | recruiting | Phase 1 / Phase 2 | 300 | University Hospital, LinkoepingOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05028933 | IMC001 for Clinical Research on Advanced Digestive System Malignancies | unknown | Phase 1 | 48 | Zhejiang UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05213195 | NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer | unknown | Phase 1 | 38 | Zhejiang UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT02215889 | Partial Liver Segment 2/3 Transplantation Study | recruiting | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05952947 | HRYZ-T101 Injection for HPV18 Positive Solid Tumor | recruiting | Phase 1 | 32 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05746897 | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 38 | Hefei TG ImmunoPharma Co., Ltd.OTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT01605318 | Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 92 | Gilead SciencesINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06010901 | A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. | unknown | Phase 1 | 75 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT04803305 | Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia | completed | Phase 1 | 18 | PfizerINDUSTRY | 2 | Jan 12, 2024 | clinicaltrials |
| NCT06200363 | A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer | unknown | Phase 1 | 15 | West China HospitalOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT04235114 | Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET) | recruiting | Phase 1 / Phase 2 | 14 | University of SaskatchewanOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05522738 | Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 46 | Chinese PLA General HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06195670 | Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC | not yet recruiting | Phase 1 / Phase 2 | 220 | Zhejiang Cancer HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04558684 | Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer | suspended | Phase 1 / Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Apr 18, 2024source: clinicaltrials